Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

HMBD-002 is the only IgG4 isotype anti-VISTA antibody currently in development HMBD-002 is anticipated to enter a Phase 1 clinical trial in 2021 HOUSTON and SINGAPORE, May 30, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing...

from PR Newswire: https://ift.tt/3uuSSxW